Federica Ruin

Federica Ruin

Auto-generated profile, based on publicly available information

Federica Ruin

Department of Systems Medicine University Hospital of Padua Padua Italy

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2026 in Clinical and Translational Allergy
Verified
Journal Article
Open access
PDF file
FPFrancesca Perego
Francesca Perego
AMAzzurra Cesoni Marcelli
Azzurra Cesoni Marcelli
RSRiccardo Senter
Riccardo Senter
LZLorenza Chiara Zingale
Lorenza Chiara Zingale
AGAntonio Gidaro
Antonio Gidaro
MCMauro Cancian
Mauro Cancian
Background: Hereditary Angioedema due to C1‐inhibitor deficiency (HAE‐C1INH) is a rare disease that affects individuals of all ages, however, older adults have never been characterized in terms of disease severity, comorbidities, and treatments. The aim was to identify the clinical characteristics of and therapeutic approaches in HAE‐C1INH patients aged 65 and older. Methods: Data from the ITACA (Italian network for Hereditary and Acquired Angioedema) Registry were prospectively collected for 10‐month. Results: Data from 647 HAE‐C1INH, patients including 343 females (53%), were collected: 114 patients (17.6%) were aged 65 and older (68 females; 58.6%). Group mean age was 74.3 ± 7.5 years, mean age at first‐symptom‐onset was 19 ± 15 years, and mean age at diagnosis was 45.6 ± 14.3 years. Common comorbidities were: hypertension (59.6%), dyslipidaemia (28.9%), coronary artery disease (14.0%), diabetes (14.0%), endocrinopathies (14.0%), neoplasia (12.3%) and B/C hepatitis (11.4%). Half of the older patients (49%) experienced at least one attack during the study period, and 8 patients (7%) had an attack frequency of > 0.5 attacks/month. Long‐term prophylaxis (LTP) was the treatment of choice in 45 patients (39.5%) and represented 15.9% of overall LTP prescriptions: 60% were treated with lanadelumab, 22.2% with attenuated androgens, 13.3% with berotralstat, and 4.5% with sub‐cutaneous C1INH concentrate. Gender differences were not detected in any of the variables analyzed. Conclusion: Older patients with HAE‐C1INH constitute a relevant subgroup, characterized by persistent disease activity and comorbidities. The availability of new therapies and guideline recommendations are driving an increase in LTP use, although shifting from older non‐specific treatments, especially androgens, is still incomplete.

2 December 2025 in bioRxiv
Verified
Preprint
Open access
HCHéctor Cañeque-Rufo
Héctor Cañeque-Rufo
AZAgata Zuccaro
Agata Zuccaro
MSMarta Inmaculada Sanz-Cuadrado
Marta Inmaculada Sanz-Cuadrado
FRFederica Ruin
Federica Ruin
ÁOÁngela Olivera-Rodriguez
Ángela Olivera-Rodriguez
MRM.Pilar Ramos-Alvarez
M.Pilar Ramos-Alvarez
Obesity is a global health problem linked to the development of metabolic syndrome (MetS) and comorbidities such as metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). These diseases are characterised by systemic inflammation, lipid accumulation and tissue damage, which contribute to liver fibrosis and dysfunction. Pleiotrophin (PTN), a cytokine known for its role in tissue regeneration and energy metabolism, has emerged as a potential regulator of liver homeostasis. Herein, we demonstrate that Ptn deletion protects against body weight gain, metainflammation and high-fat diet (HFD)-induced MASLD and MASH development. Furthermore, our work uncovers the molecular mechanisms by which PTN may promote lipid synthesis and hepatic extracellular matrix remodelling. Results highlight PTN as a critical modulator of liver metabolism and systemic inflammation in the context of obesity, identifying it as a promising therapeutic target for the treatment of MASLD, MASH and related metabolic disorders, and point to a sexual dimorphism in adaptive metabolic strategies, with females demonstrating a greater degree of protection against the liver-damaging effects of diet-induced obesity. HIGHLIGHTS: Females are more protected against the liver-damaging effects of the high-fat diet (HFD), suggesting a sexual dimorphism in adaptive metabolic strategies. PTN regulates lipid metabolism by promoting lipogenesis and lipid accumulation in liver cells through the activation of AKT and the inhibition of AMPKα; the absence of PTN reverses this process. Deletion of Ptn protects against high-fat diet (HFD)-induced weight gain, systemic inflammation, hepatic lipid accumulation, and the development of steatosis and liver fibrosis. PTN is a key modulator of metabolic, inflammatory and remodelling processes in the liver, and it is proposed as a promising therapeutic target for MASLD, MASH and other metabolic comorbidities. Graphical PTN liver signalling pathway.: acetyl-CoA carboxylase (ACC); 5’ adenosine monophosphate-activated protein kinase (AMPK); protein kinase B (AKT); aquaporin 9 (AQP9); diacylglycerides (DAG); diacylglycerol O-acyltransferase 2 (DGAT2); free fatty acids (FFA); hepatic stellate cell (HSC); insulin receptor (IR); pleiotrophin (PTN); triacylglycerides (TAG).